Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients

NCT04856124 is registered in ClinicalTrials.gov with Psych Atlanta as lead sponsor.

NCT NCT04856124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04856124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients
Lead sponsor
Psych Atlanta
Phase
Observational
Overall status
Completed
Start date
September 1, 2018
Completion date
March 1, 2021
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression